Alzheimer Portugal Presses the State to Fund the New Drugs That Slow the Disease
Alzheimer Portugal is urging the state to reimburse lecanemab and donanemab, the first drugs shown to slow early Alzheimer's, which currently cost patients up to €40,000 out of pocket while INFARMED weighs whether the SNS should fund them.